EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Changes in Saccadic Hypometria over Time to Monitor Parkinson’s Disease Progression

Edmund Ben-Ami, Eitan Raveh, Eran Harpaz, Igal Riklin, Tali Band, Tanya Gurevich, Roy N Alcalay, Pablo Mir, Michelle H S Tosin, Christopher G Goetz, Olivier Rascol iD

Pharmaceutical Medicine · 2026-07 · 40 (4) · 299-309

DOI: 10.1007/s40290-026-00612-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmaceutical Medicine, online erschienen am 30.05.2026. Verfasst von Edmund Ben-Ami und 10 weiteren Autor:innen. Beteiligte Einrichtung: NeuraLight LTD, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Parkinson Disease, Saccades. Die Arbeit nennt 62 Literaturangaben. Gefördert von: NeuraLight LTD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Eye movement biomarkers are emerging as promising tools for monitoring neurodegenerative diseases in clinical trials. Saccadic hypometria, the reduced saccade amplitude leading to undershooting visual targets, is a recognized feature of Parkinson's disease (PD), correlated with motor symptoms severity in cross-sectional studies. However, its use as a biomarker to monitor disease progression has not been studied. OBJECTIVES: The aim was to assess the sensitivity and reproducibility of saccadic hypometria as a biomarker of PD progression. METHODS: The amplitude of saccadic hypometria (ASH) was measured in two cohorts: a single-center cohort (SCC) (30 PD patients, 50 healthy controls) followed by a multicenter cohort (MCC) (250 PD patients, 91 healthy controls across 4 sites). Assessments occurred every 3 months over 9 months using a software-based platform (NeuraLight). Motor symptoms were assessed with the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III. ASH and MDS-UPDRS changes were analyzed using individual slopes of change and compared between groups. RESULTS: ASH significantly declined over time in PD patients compared to controls in both cohorts (SCC: - 1.96 ± 4.14% vs. 0.33 ± 1.75%, P < 0.01; MCC: - 1.05 ± 3.09% vs. 0.54 ± 1.85%, P < 0.001), and these changes were consistent across MCC sites. MDS-UPDRS III scores remained unchanged over the same period in the SCC, and changes were highly variable across MCC sites, resulting in a non-statistically significant change over time. CONCLUSION: ASH progressively worsened in PD patients over 9 months, even when standard clinical scales showed no significant change. These findings support ASH as a sensitive, objective, and quantitative biomarker for monitoring PD progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseSaccadesAgedFemaleHumansMaleMiddle AgedBiomarkersCohort StudiesDisease ProgressionReproducibility of ResultsSeverity of Illness IndexTime Factors

Substanzen

Biomarkers

Autor:innen und Institutionen

  • NeuraLight LTD, Tel Aviv, Israel.
  • Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel.
  • Department of Neurology, Columbia University Irving Medical Center, New York City, USA.
  • Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
  • Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Seville, Spain.

ORCID-Profile: Olivier Rascol

Förderung

  • NeuraLight LTD

Zitieren

APA

Ben-Ami, E., Raveh, E., Harpaz, E., Riklin, I., Band, T., Gurevich, T., Alcalay, R. N., Mir, P., Tosin, M. H. S., Goetz, C. G., & Rascol, O. (2026). Changes in Saccadic Hypometria over Time to Monitor Parkinson’s Disease Progression. Pharmaceutical Medicine, 40(4), 299-309. https://doi.org/10.1007/s40290-026-00612-2

Vancouver

Ben-Ami E, Raveh E, Harpaz E, Riklin I, Band T, Gurevich T, et al. Changes in Saccadic Hypometria over Time to Monitor Parkinson’s Disease Progression. Pharmaceutical Medicine. 2026;40(4):299-309. doi:10.1007/s40290-026-00612-2

BibTeX
@article{BenAmi2026,
  author = {Ben-Ami, Edmund and Raveh, Eitan and Harpaz, Eran and Riklin, Igal and Band, Tali and Gurevich, Tanya and Alcalay, Roy N and Mir, Pablo and Tosin, Michelle H S and Goetz, Christopher G and Rascol, Olivier},
  title = {Changes in Saccadic Hypometria over Time to Monitor Parkinson’s Disease Progression},
  journal = {Pharmaceutical Medicine},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {299--309},
  doi = {10.1007/s40290-026-00612-2}
}
Kostenlos starten →